Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride -: Preliminary findings

被引:187
作者
Martin, SD
Martin, E
Rai, SS
Richardson, MA
Royall, R
机构
[1] Cherry Knowle Hosp, Affin Res Unit, Sunderland SR2 0NB, England
[2] St Lukes Hosp, Hutton Ctr, Middlesbrough, Cleveland, England
[3] S Cleveland Hosp, No Reg Med Phys Dept, Middlesbrough, Cleveland, England
关键词
D O I
10.1001/archpsyc.58.7.641
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Functional brain imaging studies in major depression have suggested abnormalities of areas, including the frontal cortex, cingulate gyrus, basal ganglia, and temporal cortex. We hypothesized that venlafaxine hydrochloride and interpersonal psychotherapy (IPT) might each alter brain blood flow in some or all of these areas on sequential single photon emission computed tomography (SPECT) scans. Methods: Twenty-eight men and women aged 30 to 53 years with a DSM-IV major depressive episode, a 17-item Hamilton Rating Scale for Depression (HAM-D) rating of 18 or higher, and antidepressant-naive for at least 6 months were studied. After baseline (99m)Technetium-hexa-methyl-propylene-amine-oxime scan, 1-T magnetic resonance imaging, and psychometric ratings, patients were assigned to different treatments. Thirteen patients had 1-hour weekly sessions of IPT from the same supervised therapist (E.M.). Fifteen patients took 37.5 mg twice-daily of venlafaxine hydrochloride. Single-photon emission computed tomography scans and ratings were repeated at 6 weeks. Results: Both treatment groups improved substantially, more so with venlafaxine (mean [SD] HAM-D scores at pretreatment: IPT, 22.7 [2.7], and venlafaxine, 22.4 [3.1]; and posttreatment; IPT, 16.2 [7.1], and venlafaxine, 10.9 [8.6]). No patients had structural brain abnormalities. On analysis with statistical parametric mapping 96, the venlafaxine group showed right posterior temporal and right basal ganglia activation (P=.01), while the IPT group had limbic right posterior cingulate and right basal ganglia activation (P=.01). Conclusions: This preliminary investigation has shown limbic blood flow increase with IPT yet not velafaxine, while both treatments demonstrated increased basal ganglia blood flow. This was, however, a short trial with a small sample, no control group, and different symptom reduction in the 2 groups.
引用
收藏
页码:641 / 648
页数:8
相关论文
共 51 条
  • [1] A CLASSIFICATION OF HAND PREFERENCE BY ASSOCIATION ANALYSIS
    ANNETT, M
    [J]. BRITISH JOURNAL OF PSYCHOLOGY, 1970, 61 (03) : 303 - &
  • [2] Incorporating prior knowledge into image registration
    Ashburner, J
    Neelin, P
    Collins, DL
    Evans, A
    Friston, K
    [J]. NEUROIMAGE, 1997, 6 (04) : 344 - 352
  • [3] SINGLE PHOTON-EMISSION TOMOGRAPHY WITH TC-99M-EXAMETAZIME IN MAJOR DEPRESSION AND THE PATTERN OF BRAIN ACTIVITY UNDERLYING THE PSYCHOTIC NEUROTIC CONTINUUM
    AUSTIN, MP
    DOUGALL, N
    ROSS, M
    MURRAY, C
    OCARROLL, RE
    MOFFOOT, A
    EBMEIER, KP
    GOODWIN, GM
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1992, 26 (01) : 31 - 43
  • [4] AN INVENTORY FOR MEASURING DEPRESSION
    BECK, AT
    ERBAUGH, J
    WARD, CH
    MOCK, J
    MENDELSOHN, M
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 1961, 4 (06) : 561 - &
  • [5] Effect of sertraline on regional metabolic rate in patients with affective disorder
    Buchsbaum, MS
    Wu, J
    Siegel, BV
    Hackett, E
    Trenary, M
    Abel, L
    Reynolds, C
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 41 (01) : 15 - 22
  • [6] CARLSSON A, 1995, SCHIZOPHRENIA, P384
  • [7] COSTA DC, 1986, NUCL MED COMMUN, V7, P647
  • [8] CUNNINGHAM LA, 1994, J CLIN PSYCHOPHARM, V14, P99
  • [9] DOPAMINE D(2) RECEPTORS IN DEPRESSION MEASURED WITH SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY
    DHAENEN, HA
    BOSSUYT, A
    [J]. BIOLOGICAL PSYCHIATRY, 1994, 35 (02) : 128 - 132
  • [10] A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
    Dierick, M
    Ravizza, L
    Realini, R
    Martin, A
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1996, 20 (01) : 57 - 71